Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

This study is being done to answer the following question:

Can we lower the chance of your bladder cancer coming back by adding the drug MK-3475
(pembrolizumab) to an existing treatment option for bladder cancer?

We are doing this study because we want to find out if this approach is better or worse than the
usual approach for your bladder cancer. The usual approach is defined as care most people get
for bladder cancer.